Navigation Links
Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Date:8/22/2007

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology. These molecules and compounds could be currently available or are in pre-clinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-
'/>"/>

SOURCE Emisphere Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, today announced that ... the United States on the ... September 17, 2014 on the OTCQX under the symbol ... TSX Venture Exchange under its existing symbol SQD. ...
(Date:9/17/2014)... California , 17 de septiembre de ... ("la compañía"), principal proveedor mundial de soluciones ... las ciencias de la vida, anunció hoy ... de logística global con sede en Rótterdam, ... base de clientes Europa en rápido crecimiento. ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Belgium, May 14 , - ... Accordance With the Law of May 2, 2007 , ... company,focused on the discovery and development of innovative treatments for ... update for,the three month period ending 31 March, 2009. , ...
... the quarter increase 4.2% vs. prior year -DENVER, May 14 ... developer and marketer of diagnostic test kits, today filed its ... disclosed that the company,s sales have increased during the quarter ... prior year. Some of the results highlighted by the report ...
... Phase 2 Program Combines Histology, Biomarkers and Non-Invasive Imaging ... Vascular InflammationSAN FRANCISCO, May 14 VIA ... company focused on the development of compounds for the ... it has completed enrollment in a Phase 2 clinical ...
Cached Biology Technology:ThromboGenics NV: Business Update 2ThromboGenics NV: Business Update 3ThromboGenics NV: Business Update 4ThromboGenics NV: Business Update 5ThromboGenics NV: Business Update 6ThromboGenics NV: Business Update 7Corgenix Reports Third Quarter Fiscal 2009 Financial Results 2Corgenix Reports Third Quarter Fiscal 2009 Financial Results 3Corgenix Reports Third Quarter Fiscal 2009 Financial Results 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5
(Date:9/16/2014)... species has its own bacterial identity. That,s the conclusion ... institutions who studied the genetic fingerprints of bacteria on ... , "This study demonstrates for the first time that ... ecological strategies possess very different microbial communities on their ... postdoctoral researcher in the UO,s Institute of Ecology and ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
(Date:9/16/2014)... between viruses, bacteria, and their environment is becoming ... between Matthew Sullivan, associate professor in the University ... and Steven Hallam from the University of British ... drivers of nutrient and energy cycles that power ... changing, so are the environments these bacteria live ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3
... phenomenon that occurs in biological systems ranging from ... across thousands of kilometers. , The National ... now accepting applications for its Investigative Workshop: Synchrony ... April 11-13, 2011, at NIMBioS on the University ...
... a world first, a new ,state of the art, ... University of Queensland,s Heron Island Research Station. ... Professor Sophie Dove and Dr. David Kline from the ... of the largest and most accurately controlled ocean acidification ...
... single-cell organisms that affect oral health, Millicent "Mimi" Goldschmidt, ... The University of Texas Health Science Center at Houston ... Society for Microbiology (ASM) Founders Distinguished Service Award. ... to the society. Goldschmidt joined the ASM in 1949 ...
Cached Biology News:Conditioning reefs for the future 2UTHealth professor to receive service award from American Society for Microbiology 2
VMAT 2 (N-19)...
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
DOCK 2 (E-15)...
... by A300-183A maps to the ... human quaking homolog according to ... The epitope is not found ... 4, 6, 7 or 7B ...
Biology Products: